The largest database of trusted experimental protocols

92 protocols using cd 1 nude mice

1

Xenograft Tumor Formation in CD-1 Nude Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Heterozygous female CD-1 nude mice (Charles River, strain code 087) were intercrossed to homozygous male CD-1 nude mice (Charles River, strain code 086) to generate homozygous, athymic, nude males for use in xenograft experiments. The potential for B4 (passage 42) and C10 (passage 38) cells to form xenograft tumors was tested. Each cell line was tested in three different mice; mice that received B4 cells were littermates 47 days in age, and mice that received C10 were littermates 54 days in age. Mice were anesthetized with inhalant isoflurane for the injections. Each mouse received 5 million cells subcutaneously in the right flank. Cells were diluted in 200 μL of a 1:1 ratio of PBS and matrigel basement membrane mix (Corning). For control, 200 μl of 1:1 ratio of PBS and matrigel without cells was injected subcutaneously in the left flank. Tumor development was monitored for 6 months and diameter measurements were obtained weekly with manual calipers. Mice were euthanized via C02 asphyxiation (per IACUC approved protocol), necropsies were performed, and subcutaneous tumors were harvested and fixed in 4% paraformaldehyde. Paraffin-embedded sections were stained with hematoxylin and eosin and analyzed by a board-certified veterinary pathologist (TS).
+ Open protocol
+ Expand
2

In Vivo Sarcoma Xenograft Validation

Check if the same lab product or an alternative is used in the 5 most similar protocols
In order to validate the ability of our cell lines to form sarcomas in vivo, subcutaneous xenografts in mice were evaluated using methods previously described (Borlle et al., BMC Veterinary Research 2018, in review). Female, heterozygous CD-1 nude mice (Charles River, Strain code 087) were crossed with male, homozygous CD-1 nude mice (Charles River, Strain code 086). Resulting, male, athymic, nude littermates were injected subcutaneously in the right flank with 5 × 106 FISS cells of a given cell line suspended in 200 μl of a 1:1 solution of PBS and Matrigel (Corning) for each cell line. As a control, 200 μl of a 1:1 solution of PBS and Matrigel (Corning) without any cells was injected subcutaneously in the left flank. Tumor growth was monitored for up to 24 weeks. At the end of the monitoring period, mice were euthanized via carbon dioxide asphyxiation and necropsies were performed to collect tumor tissue. Tissues were fixed in 4% paraformaldehyde, embedded in paraffin, and stained with hematoxylin and eosin for histopathologic evaluation.
+ Open protocol
+ Expand
3

Preclinical Bone Metastasis Model Using MDA-MB-231 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
For in vivo studies, nude CD-1 mice (Charles River) were maintained under sterile conditions in ventilated cages and racks with a 12-hour light/12-hour dark cycle. At 6 weeks of age, female mice were randomized into six groups: vehicle (sham) (n = 4); parental MDA-MB-231 cells (n = 5); luciferase shRNA control vector (Luc, n = 5); shRNA for L-plastin (shL, n = 7, shRNA for peroxiredoxin-4 (shP, n = 7); shRNA for L-plastin and PRDX4 (shLP, n = 6). MDA-MB-231 cells (1 × 105 cells/mouse) in 20 μl of PBS were inoculated in the left tibia [25] (link). Mice were euthanized 2 weeks after the injection.
+ Open protocol
+ Expand
4

Calvarial Defect Healing Capacity of TWIST1 hASCs

Check if the same lab product or an alternative is used in the 5 most similar protocols
All animal experiments were performed in accordance with Stanford University Animal Care and Use Committee guidelines. For evaluating the in vivo healing capacity of TWIST1sh hASCs 21-day-old male nude CD1-mice (Charles River Laboratories, Wilmington, MA) underwent calvarial defect procedures as previously described [14 (link), 53 (link)]. Briefly, after anesthesia with an intraperitoneal injection of ketamine 100 mg/kg + xylazine 20 mg/kg + acepromazine 3 mg/kg and disinfection of the surgical site of the mice, nonhealing critical 4-mm calvarial defects were created with a trephine drill bit in left parietal bones as previously described [14 (link)]. Meticulous care was taken in order to protect the underlying dura mater or neighboring cranial sutures. Treatment groups included no treatment (empty), scaffold with serum, scaffold seeded with shTWIST1 hASCs, scaffold seeded with scramble hASCs, scaffold seeded with shTWIST1/TAZ hASCs, and scaffold seeded with shTAZ hASCs. The scaffolds were placed in the defects, the wound was closed, and the animals were allowed to recover.
+ Open protocol
+ Expand
5

Xenograft Mouse Model Establishment

Check if the same lab product or an alternative is used in the 5 most similar protocols
All animal work was performed in accordance with protocols approved by the University of Cincinnati Standing Committees on Animals. 6–8 week-old female nude CD-1 mice (Charles River), NOD/SCID-gamma mice (Jackson Lab), and CB17-scid mice (Taconic) were used.
+ Open protocol
+ Expand
6

Intracranial Grafting of CNS-1 Cells and GICs

Check if the same lab product or an alternative is used in the 5 most similar protocols
For in vivo studies using CNS-1 cells or GICs, adult female Lewis rats or nude CD-1 mice were used, respectively (Charles River Laboratory, New Brunswick, NJ). Protocols were approved by Yale University and State University of New York Upstate Medical School animal care committees.
For intracranial CNS-1 cell grafts, 1.5×105 cells in 1.5μL was injected into the right thalamus of rats at 3.2mm posterior and 2.3mm to the right of Bregma at a depth of 5.5mm. Survival was plotted according to the method of Kaplan and Meier and statistical significance was determined using the Log-Rank (Mantel-Cox) test.
For intracranial GIC grafts, 1.1×106 cells in 1.5μL was injected into the right striatum of CD-1 nude mice at 0.5mm anterior and 2.0mm to the right of Bregma at a depth of 3.5mm. Pairs of control and shB/b animals were established at the time of tumor implantation. Both animals in the pair were sacrificed when one was showing signs of neurological deterioration. To control for differences in survival times, analyses were carried out between animal pairs. Statistical analysis for survival was carried by Log-Rank (Mantel-Cox) test.
+ Open protocol
+ Expand
7

Biodistribution and SPECT/CT Imaging of AR42J Tumors

Check if the same lab product or an alternative is used in the 5 most similar protocols
All applicable international, national, and/or institutional guidelines for the care and use of laboratory animals, in particular, the guidelines of Swiss Regulations for Animal Welfare were applied. The preclinical studies were ethically approved by the responsible Committee of Animal Experimentation and permitted by the responsible cantonal authorities (license No. 75721; approval date: 25 September 2018). Five-week-old female CD-1 nude mice were purchased from Charles River Laboratories (Sulzfeld, Germany). Mice were subcutaneously inoculated with AR42J tumor cells (5 × 106 cells in 100 µL PBS) for biodistribution (n = 3–4 mice per timepoint) and SPECT/CT imaging studies (n = 2–3 mice per setting). The studies were performed 10–14 days after tumor cell inoculation when the tumor size reached a volume of ~250 mm3.
+ Open protocol
+ Expand
8

Xenograft Tumor Growth Measurement

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell lines and tumour fragments derived from the mouse angiosarcomas were injected into both flanks of 6- to 8-week-old female CD-1 nude mice (Charles River) and tumour growth measured twice weekly using calipers. Tumour volumes were calculated in Excel using the formula v=4/3πr3. Animals were sacrificed when tumours reached the maximum size allowed, and collected and fixed in 10% neutral buffered formalin.
+ Open protocol
+ Expand
9

Mouse Xenograft Model Establishment

Check if the same lab product or an alternative is used in the 5 most similar protocols
Female C57BL/6 and CD-1 nude mice were purchased from Charles River Laboratory. All mice were used at age 6–8 weeks and held under specific pathogen–free conditions with humidity and temperature control. Mice were randomly divided into groups in each experiment.
+ Open protocol
+ Expand
10

Targeted Therapy for HER2-Positive Tumors

Check if the same lab product or an alternative is used in the 5 most similar protocols
KPL-4 cells (5×106 per mouse) in a 1:1 mixture of PBS and BD Matrigel (BD Bioscience) were inoculated subcutaneously into the mammary fat pad of 7-weeks old female CD-1 nude mice (Charles River Laboratories). When tumors reached ~100 mm3, the mice were randomly assigned to 5 groups of 5 mice each and treated with anti-HER2 scFv-Fc-Sec/CN29 at 1 mg/kg or 3 mg/kg, or with unconjugated anti-HER2 scFv-Fc-Sec at 3 mg/kg, or with vehicle (PBS) alone, or with ado-trastuzumab emtansine biosimilar (Levena Biopharma) at 1 mg/kg by i.v. (tail vein) injection every 4 days for a total of 4 cycles. The tumor size was monitored every other day using caliper measurement.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!